GlassScriptPhysician profile
Brian D Page
NPI 1457382897
$1,949.19
in general payments reported to CMS, 2019-2025
34 companies · $35.33 in 2025
The $35.33 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,325 · 2022: $22.82 · 2023: $23.20 · 2024: $542 · 2025: $35.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $502 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $501.95 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $235.39 | 2021-2024 | Jakafi, Pemazyre, Monjuvi |
| Gilead Sciences, INC. | $207.38 | 2024 | Trodelvy |
| Array Biopharma INC | $146.97 | 2021-2024 | Mektovi, Braftovi, Lorbrena |
| Astellas Pharma US INC | $129.38 | 2021-2024 | Xospata |
| Janssen Biotech, INC. | $124.83 | 2021-2025 | Darzalex, Imbruvica, Talvey |
| E.R. Squibb & Sons, L.L.C. | $109.67 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $105.77 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $87.11 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $69.08 | 2021 | |
| Glaxosmithkline, LLC. | $63.22 | 2021 | |
| Pfizer INC. | $61.00 | 2021-2024 | |
| Deciphera Pharmaceuticals INC. | $44.22 | 2021 | |
| Seagen INC. | $43.52 | 2021 | |
| Celgene Corporation | $42.39 | 2021 | |
| Kite Pharma, INC. | $39.21 | 2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $36.26 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.34 | 2021 | |
| Amag Pharmaceuticals, INC. | $31.71 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $29.66 | 2021 | |
| Beigene USA, INC. | $25.00 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.53 | 2021 | |
| Abbvie INC. | $24.44 | 2021 | |
| Blueprint Medicines Corporation | $23.59 | 2021 | |
| Genentech USA, INC. | $23.13 | 2021 | |
| Morphosys, US INC. | $22.85 | 2021 | |
| Daiichi Sankyo INC. | $22.50 | 2021 | |
| Jazz Pharmaceuticals INC. | $22.14 | 2021 | |
| Alexion Pharmaceuticals, INC. | $20.89 | 2021 | |
| Foundation Medicine, INC. | $20.56 | 2021 | |
| Lilly USA, LLC | $17.04 | 2021 | |
| Tempus Ai, INC | $17.00 | 2025 | Xt Cdx |
| Novartis Pharmaceuticals Corporation | $16.98 | 2021 | |
| Chiesi USA, INC. | $15.65 | 2021 | |
| Dova Pharmaceuticals | $11.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Page listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.